Placebo News and Research

RSS

Tirzepatide rewires appetite and slashes calorie intake in new obesity trial

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain imaging revealed that tirzepatide also lowered neural responses to high-fat, high-sugar food cues, offering mechanistic insight into its potent weight-loss effects.

25 Jun 2025

Do omega-3 supplements boost athletic performance?

Combining omega-3 supplementation with resistance training significantly improved lipid profiles, inflammation markers, antioxidant capacity, and neuromuscular performance in healthy men. While group × time effects weren’t significant, within-group gains suggest real physiological benefits.

25 Jun 2025

Is aspartame safe for blood sugar? Study answers the big question

A major systematic review and meta-analysis found that aspartame has little to no effect on blood glucose, insulin, or appetite-regulating hormones in humans. Evidence certainty is very low, with no significant long-term metabolic impact identified.

25 Jun 2025

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in adults with obesity, with or without diabetes, in a phase 2 randomized trial. The drug demonstrated an acceptable safety profile and supports further study in phase 3 trials.

24 Jun 2025

Clinical trial finds new benefits of semaglutide for adults with type 1 diabetes

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with Type 1 diabetes who use automated insulin delivery systems.

23 Jun 2025

Cagrilintide and semaglutide together drive record weight loss in global trial

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful weight loss in adults with obesity but no diabetes. The combination outperformed either drug alone and improved multiple cardiometabolic health markers.

23 Jun 2025

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b/2a trial. The treatment was generally well tolerated, with mostly mild to moderate gastrointestinal side effects, supporting further investigation in larger, longer studies.

23 Jun 2025

Cannabidiol may help reduce problematic behaviors in autistic boys

Researchers at the Center for Medicinal Cannabis Research at University of California San Diego School of Medicine have found that cannabidiol (CBD), a non-intoxicating compound found in cannabis, could help reduce problematic behaviors in autistic boys.

23 Jun 2025

Qureight's synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment

Qureight, a deep-learning analytics company accelerating drug development through AI-powered data curation, today announced that its digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research.

17 Jun 2025

Single-dose of psilocybin shows long-term relief for depression in cancer patients

New results from a clinical trial reveal that a single dose of psilocybin-a naturally occurring psychedelic compound found in mushrooms-can provide sustained reductions in depression and anxiety in individuals with cancer suffering from major depressive disorder.

16 Jun 2025

Two existing medications work effectively together in treating alcohol use disorder

Two existing medications - one used for smoking cessation and the other for depression - appear to work effectively together in treating alcohol use disorder.

16 Jun 2025

Empagliflozin preserves kidney function in heart attack patients

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease.

13 Jun 2025

Low-dose vitamin D supplements can increase effectiveness of chemotherapy in breast cancer patients

A study conducted at the Botucatu School of Medicine at São Paulo State University (FMB-UNESP) in Brazil has shown that low-dose vitamin D supplementation can increase the effectiveness of chemotherapy treatment in women with breast cancer.

13 Jun 2025

Weight loss drug semaglutide proven safe and effective for people with schizophrenia

Diabetic weight loss medications are effective for people with schizophrenia without affecting psychotic symptoms, University of Queensland researchers have found.

10 Jun 2025

Using causal machine learning to identify potential ALS treatments

Potential treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases may already be out there in the form of drugs prescribed for other conditions.

10 Jun 2025

Creatine offers broad health benefits beyond fitness

Creatine, the supplement popular with athletes for its ability to help build strength and power, is increasingly being recognized for its broad health benefits.

9 Jun 2025

In axing mRNA contract, Trump delivers another blow to US biosecurity, former officials say

The Trump administration's cancellation of $766 million in contracts to develop mRNA vaccines against potential pandemic flu viruses is the latest blow to national defense, former health security officials said.

6 Jun 2025

Nicotinamide riboside shows promise in treating Werner syndrome symptoms

Werner syndrome (WS) is a rare genetic disorder that causes premature aging and serious complications. In the first clinical trial of its kind, researchers from Japan with the company Niagen Bioscience, investigated the effects of nicotinamide riboside (NR), a vitamin B3 derivative, in patients with WS.

5 Jun 2025

Type 2 diabetes drug shows improvements for patients with progressive liver disease

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical trial from China published by The BMJ today.

5 Jun 2025

Common antibiotic shows promise in reducing preterm births

A study of almost 1000 pregnant women in Zimbabwe found that a daily dose of a commonly used, safe and inexpensive antibiotic may have led to fewer babies being born early.

5 Jun 2025

Placebo News and Research

Tirzepatide rewires appetite and slashes calorie intake in new obesity trial

Do omega-3 supplements boost athletic performance?

Is aspartame safe for blood sugar? Study answers the big question

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

Clinical trial finds new benefits of semaglutide for adults with type 1 diabetes

Cagrilintide and semaglutide together drive record weight loss in global trial

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

Cannabidiol may help reduce problematic behaviors in autistic boys

Qureight's synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment

Single-dose of psilocybin shows long-term relief for depression in cancer patients

Two existing medications work effectively together in treating alcohol use disorder

Empagliflozin preserves kidney function in heart attack patients

Low-dose vitamin D supplements can increase effectiveness of chemotherapy in breast cancer patients

Weight loss drug semaglutide proven safe and effective for people with schizophrenia

Using causal machine learning to identify potential ALS treatments

Creatine offers broad health benefits beyond fitness

In axing mRNA contract, Trump delivers another blow to US biosecurity, former officials say

Nicotinamide riboside shows promise in treating Werner syndrome symptoms

Type 2 diabetes drug shows improvements for patients with progressive liver disease

Common antibiotic shows promise in reducing preterm births

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News